Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

Kaptein et al., bioRxiv, doi:10.1101/2020.06.19.159053

Jun 2020

Source PDF All Studies Meta AnalysisMeta

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 419 studies, recognized in 46 countries.

Lower risk for mortality, hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19hcq.org

Animal study with Syrian hamsters, showing treatment of SARS-CoV-2-infected hamsters with favipiravir or HCQ (with and without AZ). Treatment with HCQ alone resulted in a very modest reduction of 0.3 log10 viral RNA copies/mg lung, and no reduction in viral RNA load in the ileum or stool.

Therapeutic levels of HCQ may not have been reached. Cytosolic concentrations in the lung were far below the EC90 target.

A number of issues have reportedly been raised, including the following, for which the authors did not respond:

- HCQ was administered with DMSO and Cremophor - why were non-neutral carriers chosen? DMSO has anti-inflammatory properties and Cremophor has a range of side effects1: "use has been associated with severe anaphylactoid hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns, aggregation of erythrocytes and peripheral neuropathy". Why weren't the same amounts of solvent applied to the non-treated animals? Shouldn't favipiravir have been dissolved in the same way to avoid bias?

- Why is the method of administration different for both products (oral gavage/intraperitoneal injection)?

- One of the HCQ protocols used in France (IHU Marseille) prescribes 600mg of HCQ per day to patients. For a body weight of 60kg, this corresponds to a dose of 10mg/kg. How is a dose of 50 mg/kg in this study justified, i.e. 5 times more, with possible systemic effects on the animals and possible influence on the results?

- Why were the animals killed after 4/5 days and did the treatment not continue? Unfortunately, this does not allow us to know the real course of the disease or the mortality of the animals beyond day 4. Is it because the animals spontaneously improve without treatment as Professor Neyts seems to say in his webinar for the GVN? And if this is indeed the case, isn't the use of these hamsters exactly an objection as a model for COVID-19 research?

38 preclinical studies support the efficacy of HCQ for COVID-19:

11 In Silico studies2-12

24 In Vitro studies2,13-35

3 In Vivo animal studies17,27,36

Important missing comments or errors? Let us know.

Study covers favipiravir and HCQ.

1. sciencedirect.com, www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cremophor.www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cremophor.

2. González-Paz et al., Biophysical Analysis of Potential Inhibitors of SARS-CoV-2 Cell Recognition and Their Effect on Viral Dynamics in Different Cell Types: A Computational Prediction from In Vitro Experimental Data, ACS Omega, doi:10.1021/acsomega.3c06968.acs.org, doi.org.

3. Alkafaas et al., A study on the effect of natural products against the transmission of B.1.1.529 Omicron, Virology Journal, doi:10.1186/s12985-023-02160-6.biomedcentral.com, doi.org.

4. Guimarães Silva et al., Are Non-Structural Proteins From SARS-CoV-2 the Target of Hydroxychloroquine? An in Silico Study, ACTA MEDICA IRANICA, doi:10.18502/acta.v61i2.12533.kne-publishing.com, doi.org.

5. Nguyen et al., The Potential of Ameliorating COVID-19 and Sequelae From Andrographis paniculata via Bioinformatics, Bioinformatics and Biology Insights, doi:10.1177/11779322221149622.sagepub.com, doi.org.

6. Navya et al., A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection, Informatics in Medicine Unlocked, doi:10.1016/j.imu.2021.100714.sciencedirect.com, doi.org.

7. Yadav et al., Repurposing the Combination Drug of Favipiravir, Hydroxychloroquine and Oseltamivir as a Potential Inhibitor Against SARS-CoV-2: A Computational Study, Research Square, doi:10.21203/rs.3.rs-628277/v1.researchsquare.com, doi.org.

8. Hussein et al., Molecular Docking Identification for the efficacy of Some Zinc Complexes with Chloroquine and Hydroxychloroquine against Main Protease of COVID-19, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129979.sciencedirect.com, doi.org.

9. Baildya et al., Inhibitory capacity of Chloroquine against SARS-COV-2 by effective binding with Angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.129891.sciencedirect.com, doi.org.

10. Noureddine et al., Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: molecular docking and DFT calculations, Journal of King Saud University - Science, doi:10.1016/j.jksus.2020.101334.sciencedirect.com, doi.org.

11. Tarek et al., Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention, European Journal of Drug Metabolism and Pharmacokinetics, doi:10.1007/s13318-020-00640-6.springer.com, doi.org.

12. Rowland Yeo et al., Impact of Disease on Plasma and Lung Exposure of Chloroquine, Hydroxychloroquine and Azithromycin: Application of PBPK Modeling, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1955.wiley.com, doi.org.

13. Hitti et al., Hydroxychloroquine attenuates double-stranded RNA-stimulated hyper-phosphorylation of tristetraprolin/ZFP36 and AU-rich mRNA stabilization, Immunology, doi:10.1111/imm.13835.wiley.com, doi.org.

14. Yan et al., Super-resolution imaging reveals the mechanism of endosomal acidification inhibitors against SARS-CoV-2 infection, ChemBioChem, doi:10.1002/cbic.202400404.wiley.com, doi.org.

15. Mohd Abd Razak et al., In Vitro Anti-SARS-CoV-2 Activities of Curcumin and Selected Phenolic Compounds, Natural Product Communications, doi:10.1177/1934578X231188861.sagepub.com, doi.org.

16. Alsmadi et al., The In Vitro, In Vivo, and PBPK Evaluation of a Novel Lung-Targeted Cardiac-Safe Hydroxychloroquine Inhalation Aerogel, AAPS PharmSciTech, doi:10.1208/s12249-023-02627-3.springer.com, doi.org.

17. Wen et al., Cholinergic α7 nAChR signaling suppresses SARS-CoV-2 infection and inflammation in lung epithelial cells, Journal of Molecular Cell Biology, doi:10.1093/jmcb/mjad048.oup.com, doi.org.

18. Kamga Kapchoup et al., In vitro effect of hydroxychloroquine on pluripotent stem cells and their cardiomyocytes derivatives, Frontiers in Pharmacology, doi:10.3389/fphar.2023.1128382.frontiersin.org, doi.org.

19. Milan Bonotto et al., Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection, Antiviral Research, doi:10.1016/j.antiviral.2023.105655.sciencedirect.com, doi.org.

20. Miao et al., SIM imaging resolves endocytosis of SARS-CoV-2 spike RBD in living cells, Cell Chemical Biology, doi:10.1016/j.chembiol.2023.02.001.sciencedirect.com, doi.org.

21. Yuan et al., Hydroxychloroquine blocks SARS-CoV-2 entry into the endocytic pathway in mammalian cell culture, Communications Biology, doi:10.1038/s42003-022-03841-8.nature.com, doi.org.

22. Faísca et al., Enhanced In Vitro Antiviral Activity of Hydroxychloroquine Ionic Liquids against SARS-CoV-2, Pharmaceutics, doi:10.3390/pharmaceutics14040877.mdpi.com, doi.org.

23. Delandre et al., Antiviral Activity of Repurposing Ivermectin against a Panel of 30 Clinical SARS-CoV-2 Strains Belonging to 14 Variants, Pharmaceuticals, doi:10.3390/ph15040445.mdpi.com, doi.org.

24. Purwati et al., An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia, PLOS One, doi:10.1371/journal.pone.0252302.plos.org, doi.org.

25. Zhang et al., SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination, Cell Death & Differentiation, doi:10.1038/s41418-021-00782-3.nature.com, doi.org.

26. Dang et al., Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein, bioRxiv, doi:10.1101/2021.03.16.435741.biorxiv.org, doi.org.

27. Shang et al., Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice, Virology Journal, doi:10.1186/s12985-021-01515-1.biomedcentral.com, doi.org.

28. Wang et al., Chloroquine and hydroxychloroquine as ACE2 blockers to inhibit viropexis of 2019-nCoV Spike pseudotyped virus, Phytomedicine, doi:10.1016/j.phymed.2020.153333.nih.gov, doi.org.

29. Sheaff, R., A New Model of SARS-CoV-2 Infection Based on (Hydroxy)Chloroquine Activity, bioRxiv, doi:10.1101/2020.08.02.232892.biorxiv.org, doi.org.

30. Ou et al., Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2, PLOS Pathogens, doi:10.1371/journal.ppat.1009212.plos.org, doi.org.

31. Andreani et al., In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect, Microbial Pathogenesis, doi:10.1016/j.micpath.2020.104228.sciencedirect.com, doi.org.

32. Clementi et al., Combined Prophylactic and Therapeutic Use Maximizes Hydroxychloroquine Anti-SARS-CoV-2 Effects in vitro, Front. Microbiol., 10 July 2020, doi:10.3389/fmicb.2020.01704.frontiersin.org, doi.org.

33. Liu et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discovery 6, 16 (2020), doi:10.1038/s41421-020-0156-0.nature.com, doi.org.

34. Yao et al., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 2020 Mar 9, doi:10.1093/cid/ciaa237.oup.com, doi.org.

35. Wang (B) et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. 30, 269–271, doi:10.1038/s41422-020-0282-0.nature.com, doi.org.

36. Shu-Han Lin et al., Inhalable Chitosan-Based Hydrogel as a Mucosal Adjuvant for Hydroxychloroquine in the Treatment for SARS-CoV-2 Infection in a Hamster Model, Journal of Microbiology, Immunology and Infection, doi:10.1016/j.jmii.2023.08.001.sciencedirect.com, doi.org.

Kaptein et al., 19 Jun 2020, peer-reviewed, 35 authors.

This Paper HCQ All

Abstract: Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity a Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; bBiomedical MRI and Molecular Small Animal Imaging Centre, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; cDrug Delivery & Disposition, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven, 3000 Leuven, Belgium; dUnité des Virus Emergents, Aix Marseille University, Institut de Recherche pour le Développement (IRD) 190, Institut National de la Santé et de la Recherche Médicale (INSERM) 1207, 13005 Marseille, France; eUCL Great Ormond Street Institute of Child Health, University College London, WC1N 1EH London, United Kingdom; f Molecular Small Animal Imaging Centre, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; gDepartment of Laboratory Medicine, Ghent University Hospital, 9000 Ghent, Belgium; hNuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; iAssistance Publique–Hôpitaux de Marseille, Aix-Marseille University, Unité des Virus Emergents, Institut de Recherche pour le Développement (IRD) 190, Institut National de la Santé et de la Recherche Médicale (INSERM) 1207, Laboratoire de Pharmacocinétique et Toxicologie, 13005 Marseille, France; jTranslational Cell and Tissue Research, Department of Imaging and Pathology, Katholieke Universiteit Leuven, B-3000 Leuven, Belgium; kPharmacy Department, University Hospitals Leuven, 3000 Leuven, Belgium; lDepartment of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit Leuven–University of Leuven, 3000 Leuven, Belgium; and mGlobal Virus Network, Baltimore, MD 21201 Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 3, 2020 (received for review July 9, 2020) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options available, the virus has infected millions of people of which more than half a million succumbed to the viral disease, COVID-19. The urgent need for an effective treatment together with a lack of small animal infection models has led to clinical trials using repurposed drugs without preclinical evidence of their in vivo efficacy. We established an infection model in Syrian hamsters to evaluate the efficacy of small molecules on both infection and transmission. Treatment of SARS-CoV-2−infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, respectively, a mild or no reduction in virus levels. However, high doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. Moreover, a high dose of favipiravir decreased virus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis. Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposure to the drug did not cause the failure. Our data on hydroxychloroquine (together with previous reports in macaques and ferrets) thus provide no scientific basis for the..

{ 'institution': [{'name': 'bioRxiv'}], 'indexed': { 'date-parts': [[2023, 11, 13]], 'date-time': '2023-11-13T15:16:02Z', 'timestamp': 1699888562329}, 'posted': {'date-parts': [[2020, 6, 19]]}, 'group-title': 'Microbiology', 'reference-count': 46, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2020, 6, 19]]}, 'abstract': 'AbstractSARS-CoV-2 rapidly spread around the globe after its ' 'emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options ' 'available, the virus was able to infect millions of people. To date, close to half a million ' 'patients succumbed to the viral disease, COVID-19. The high need for treatment options, ' 'together with the lack of small animal models of infection has led to clinical trials with ' 'repurposed drugs before any preclinicalin vivoevidence attesting ' 'their efficacy was available. We used Syrian hamsters to establish a model to evaluate ' 'antiviral activity of small molecules in both an infection and a transmission setting. Upon ' 'intranasal infection, the animals developed high titers of SARS-CoV-2 in the lungs and ' 'pathology similar to that observed in mild COVID-19 patients. Treatment of ' 'SARS-CoV-2-infected hamsters with favipiravir or hydroxychloroquine (with and without ' 'azithromycin) resulted in respectively a mild or no reduction in viral RNA and infectious ' 'virus. Micro-CT scan analysis of the lungs showed no improvement compared to non-treated ' 'animals, which was confirmed by histopathology. In addition, both compounds did not prevent ' 'virus transmission through direct contact and thus failed as prophylactic treatments. By ' 'modelling the PK profile of hydroxychloroquine based on the trough plasma concentrations, we ' 'show that the total lung exposure to the drug was not the limiting factor. In conclusion, we ' 'here characterized a hamster infection and transmission model to be a robust model for ' 'studyingin vivoefficacy of antiviral compounds. The information ' 'acquired using hydroxychloroquine and favipiravir in this model is of critical value to those ' 'designing (current and) future clinical trials. At this point, the data here presented on ' 'hydroxychloroquine either alone or combined with azithromycin (together with previously ' 'reportedin vivodata in macaques and ferrets) provide no scientific ' 'basis for further use of the drug in humans.', 'DOI': '10.1101/2020.06.19.159053', 'type': 'posted-content', 'created': {'date-parts': [[2020, 6, 20]], 'date-time': '2020-06-20T04:25:12Z', 'timestamp': 1592627112000}, 'source': 'Crossref', 'is-referenced-by-count': 17, 'title': 'Antiviral treatment of SARS-CoV-2-infected hamsters reveals a weak effect of favipiravir and a ' 'complete lack of effect for hydroxychloroquine', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-7935-0219', 'authenticated-orcid': False, 'given': 'Suzanne JF', 'family': 'Kaptein', 'sequence': 'first', 'affiliation': []}, {'given': 'Sofie', 'family': 'Jacobs', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lana', 'family': 'Langendries', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laura', 'family': 'Seldeslachts', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sebastiaan', 'family': 'ter Horst', 'sequence': 'additional', 'affiliation': []}, {'given': 'Laurens', 'family': 'Liesenborghs', 'sequence': 'additional', 'affiliation': []}, {'given': 'Bart', 'family': 'Hens', 'sequence': 'additional', 'affiliation': []}, {'given': 'Valentijn', 'family': 'Vergote', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elisabeth', 'family': 'Heylen', 'sequence': 'additional', 'affiliation': []}, {'given': 'Elke', 'family': 'Maas', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carolien', 'family': 'De Keyzer', 'sequence': 'additional', 'affiliation': []}, {'given': 'Lindsey', 'family': 'Bervoets', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jasper', 'family': 'Rymenants', 'sequence': 'additional', 'affiliation': []}, {'given': 'Tina', 'family': 'Van Buyten', 'sequence': 'additional', 'affiliation': []}, {'given': 'Hendrik Jan', 'family': 'Thibaut', 'sequence': 'additional', 'affiliation': []}, {'given': 'Kai', 'family': 'Dallmeier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Robbert', 'family': 'Boudewijns', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jens', 'family': 'Wouters', 'sequence': 'additional', 'affiliation': []}, {'given': 'Patrick', 'family': 'Augustijns', 'sequence': 'additional', 'affiliation': []}, {'given': 'Nick', 'family': 'Verougstraete', 'sequence': 'additional', 'affiliation': []}, {'given': 'Christopher', 'family': 'Cawthorne', 'sequence': 'additional', 'affiliation': []}, {'given': 'Birgit', 'family': 'Weynand', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3525-7351', 'authenticated-orcid': False, 'given': 'Pieter', 'family': 'Annaert', 'sequence': 'additional', 'affiliation': []}, {'given': 'Isabel', 'family': 'Spriet', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5633-3993', 'authenticated-orcid': False, 'given': 'Greetje Vande', 'family': 'Velde', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0033-7514', 'authenticated-orcid': False, 'given': 'Johan', 'family': 'Neyts', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joana', 'family': 'Rocha-Pereira', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8874-675X', 'authenticated-orcid': False, 'given': 'Leen', 'family': 'Delang', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'reference': [ { 'key': '2020062211353215000_2020.06.19.159053v1.1', 'doi-asserted-by': 'publisher', 'DOI': '10.1056/NEJMoa2001017'}, { 'key': '2020062211353215000_2020.06.19.159053v1.2', 'doi-asserted-by': 'crossref', 'unstructured': 'Tay MZ , Poh CM , Rénia L , MacAry PA , Ng LFP. The trinity of COVID-19: ' 'immunity, inflammation and intervention. Nat Rev Immunol 2020; 1–12.', 'DOI': '10.1038/s41577-020-0311-8'}, { 'key': '2020062211353215000_2020.06.19.159053v1.3', 'doi-asserted-by': 'crossref', 'unstructured': 'Zhang B , Zhou X , Qiu Y , et al. Clinical characteristics of 82 death ' 'cases with COVID-19. medRxiv 2020; 2020.02.26.20028191.', 'DOI': '10.1371/journal.pone.0235458'}, { 'key': '2020062211353215000_2020.06.19.159053v1.4', 'doi-asserted-by': 'crossref', 'unstructured': 'Delang L , Neyts J. Medical treatment options for COVID-19. Eur Hear J ' 'Acute Cardiovasc Care 2020; published online May 4.', 'DOI': '10.1177/2048872620922790'}, { 'key': '2020062211353215000_2020.06.19.159053v1.5', 'doi-asserted-by': 'crossref', 'unstructured': 'Jeon S , Ko M , Lee J , et al. Identification of antiviral drug ' 'candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents ' 'Chemother 2020.', 'DOI': '10.1101/2020.03.20.999730'}, { 'key': '2020062211353215000_2020.06.19.159053v1.6', 'unstructured': 'Weston S , Haupt R , Logue J , Matthews K , Frieman M. FDA approved ' 'drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro. ' 'bioRxiv 2020; 2020.03.25.008482.'}, { 'key': '2020062211353215000_2020.06.19.159053v1.7', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.bbrc.2004.08.085'}, { 'key': '2020062211353215000_2020.06.19.159053v1.8', 'doi-asserted-by': 'publisher', 'DOI': '10.1128/AAC.03011-14'}, { 'key': '2020062211353215000_2020.06.19.159053v1.9', 'doi-asserted-by': 'crossref', 'unstructured': 'Delang L , Abdelnabi R , Neyts J. Favipiravir as a potential ' 'countermeasure against neglected and emerging RNA viruses. Antiviral Res ' '2018; 153.', 'DOI': '10.1016/j.antiviral.2018.03.003'}, { 'key': '2020062211353215000_2020.06.19.159053v1.10', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41422-020-0282-0'}, { 'key': '2020062211353215000_2020.06.19.159053v1.11', 'doi-asserted-by': 'crossref', 'first-page': '104786', 'DOI': '10.1016/j.antiviral.2020.104786', 'article-title': 'Remdesivir, lopinavir, emetine, and homoharringtonine inhibit ' 'SARS-CoV-2 replication in vitro', 'volume': '178', 'year': '2020', 'journal-title': 'Antiviral Res'}, { 'key': '2020062211353215000_2020.06.19.159053v1.12', 'doi-asserted-by': 'crossref', 'unstructured': 'Shannon A , Selisko B , Le T-T-N , et al. Favipiravir strikes the ' 'SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv 2020; ' '2020.05.15.098731.', 'DOI': '10.1101/2020.05.15.098731'}, { 'key': '2020062211353215000_2020.06.19.159053v1.13', 'doi-asserted-by': 'crossref', 'unstructured': 'Mehra MR , Desai SS , Ruschitzka F , Patel AN. Hydroxychloroquine or ' 'chloroquine with or without a macrolide for treatment of COVID-19: a ' 'multinational registry analysis. Lancet 2020.', 'DOI': '10.1016/S0140-6736(20)31180-6'}, { 'key': '2020062211353215000_2020.06.19.159053v1.14', 'doi-asserted-by': 'crossref', 'unstructured': 'Maisonnasse P , Guedj J , Contreras V , et al. Hydroxychloroquine in the ' 'treatment and prophylaxis of SARS-CoV-2 infection in non-human primates. ' 'Res Sq 2020.', 'DOI': '10.21203/rs.3.rs-27223/v1'}, { 'key': '2020062211353215000_2020.06.19.159053v1.15', 'unstructured': 'Chan JFW , Zhang AJ , Yuan S , et al. Simulation of the clinical and ' 'pathological manifestations of Coronavirus Disease 2019 (COVID-19) in ' 'golden Syrian hamster model: implications for disease pathogenesis and ' 'transmissibility. Clin Infect Dis 2020.'}, { 'key': '2020062211353215000_2020.06.19.159053v1.16', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2020.04.23.056838'}, { 'key': '2020062211353215000_2020.06.19.159053v1.17', 'first-page': '2000178', 'article-title': 'First cases of coronavirus disease 2019 (COVID-19) in the WHO European ' 'Region, 24 January to 21 February 2020', 'volume': '25', 'year': '2020', 'journal-title': 'Eurosurveillance'}, { 'key': '2020062211353215000_2020.06.19.159053v1.18', 'doi-asserted-by': 'crossref', 'unstructured': 'Sia SF , Yan L-M , Chin AWH , et al. Pathogenesis and transmission of ' 'SARS-CoV-2 in golden hamsters. Nature 2020.', 'DOI': '10.21203/rs.3.rs-20774/v1'}, { 'key': '2020062211353215000_2020.06.19.159053v1.19', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/j.1365-2125.1988.tb05281.x'}, { 'key': '2020062211353215000_2020.06.19.159053v1.20', 'doi-asserted-by': 'crossref', 'first-page': '598', 'DOI': '10.1002/chir.530070807', 'article-title': 'Stereoselective disposition of hydroxychloroquine and its metabolites ' 'in rats', 'volume': '7', 'year': '1995', 'journal-title': 'Chirality'}, { 'key': '2020062211353215000_2020.06.19.159053v1.21', 'doi-asserted-by': 'crossref', 'unstructured': 'Yao X , Ye F , Zhang M , et al. In Vitro Antiviral Activity and ' 'Projection of Optimized Dosing Design of Hydroxychloroquine for the ' 'Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 ' '(SARS-CoV-2). Clin Infect Dis 2020; ciaa237.', 'DOI': '10.1093/cid/ciaa237'}, { 'key': '2020062211353215000_2020.06.19.159053v1.22', 'doi-asserted-by': 'crossref', 'unstructured': 'Touret F , Gilles M , Barral K , et al. In vitro screening of a FDA ' 'approved chemical library reveals potential inhibitors of SARS-CoV-2 ' 'replication. bioRxiv 2020; 2020.04.03.023846.', 'DOI': '10.1101/2020.04.03.023846'}, { 'key': '2020062211353215000_2020.06.19.159053v1.23', 'first-page': '1', 'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is ' 'effective in inhibiting SARS-CoV-2 infection in vitro', 'volume': '6', 'year': '2020', 'journal-title': 'Cell Discov'}, { 'key': '2020062211353215000_2020.06.19.159053v1.24', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/oxfordjournals.aje.a118408'}, { 'key': '2020062211353215000_2020.06.19.159053v1.25', 'doi-asserted-by': 'crossref', 'first-page': '3305', 'DOI': '10.1109/TNS.2013.2275994', 'article-title': 'Iterative CT Reconstruction Using Shearlet-Based Regularization', 'volume': '60', 'year': '2013', 'journal-title': 'IEEE Trans Nucl Sci'}, { 'key': '2020062211353215000_2020.06.19.159053v1.26', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/s41598-019-40055-1'}, { 'key': '2020062211353215000_2020.06.19.159053v1.27', 'doi-asserted-by': 'crossref', 'first-page': '91', 'DOI': '10.1242/dmm.020321', 'article-title': 'Longitudinal micro-CT provides biomarkers of lung disease that can be ' 'used to assess the effect of therapy in preclinical mouse models, and ' 'reveal compensatory changes in lung volume', 'volume': '9', 'year': '2016', 'journal-title': 'DMM Dis Model Mech'}, { 'key': '2020062211353215000_2020.06.19.159053v1.28', 'doi-asserted-by': 'publisher', 'DOI': '10.1038/labinvest.2016.45'}, { 'key': '2020062211353215000_2020.06.19.159053v1.29', 'doi-asserted-by': 'crossref', 'unstructured': 'Garcia-Cremades M , Solans BP , Hughes E , et al. Optimizing ' 'Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative ' 'Modeling Approach for Effective Drug Re-purposing. Clin Pharmacol Ther ' '2020; cpt.1856.', 'DOI': '10.1002/cpt.1856'}, { 'key': '2020062211353215000_2020.06.19.159053v1.30', 'doi-asserted-by': 'crossref', 'unstructured': 'Quiros Roldan E , Biasiotto G , Magro P , Zanella I. The possible ' 'mechanisms of action of 4-aminoquinolines ' '(chloroquine/hydroxychloroquine) against Sars-Cov-2 infection ' '(COVID-19): A role for iron homeostasis? Pharmacol Res 2020; 158.', 'DOI': '10.1016/j.phrs.2020.104904'}, { 'key': '2020062211353215000_2020.06.19.159053v1.31', 'doi-asserted-by': 'crossref', 'first-page': '704', 'DOI': '10.1016/j.chom.2020.03.023', 'article-title': 'Infection and Rapid Transmission of SARS-CoV-2 in Ferrets', 'volume': '27', 'year': '2020', 'journal-title': 'Cell Host Microbe'}, { 'key': '2020062211353215000_2020.06.19.159053v1.32', 'doi-asserted-by': 'crossref', 'unstructured': 'Munster VJ , Feldmann F , Williamson BN , et al. Respiratory disease in ' 'rhesus macaques inoculated with SARS-CoV-2. Nature 2020; 1–7.', 'DOI': '10.1038/s41586-020-2324-7'}, { 'key': '2020062211353215000_2020.06.19.159053v1.33', 'doi-asserted-by': 'crossref', 'unstructured': 'Park S-J , Yu K-M , Kim Y-I , et al. Antiviral Efficacies of ' 'FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets. MBio 2020; ' '11.', 'DOI': '10.1128/mBio.01114-20'}, { 'key': '2020062211353215000_2020.06.19.159053v1.34', 'first-page': 'eabb7314', 'article-title': 'Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman ' 'primate model', 'volume': '368', 'year': '2020', 'journal-title': 'Science (80-)'}, { 'key': '2020062211353215000_2020.06.19.159053v1.35', 'doi-asserted-by': 'publisher', 'DOI': '10.1126/science.abb7015'}, { 'key': '2020062211353215000_2020.06.19.159053v1.36', 'doi-asserted-by': 'crossref', 'unstructured': 'Cleary SJ , Pitchford SC , Amison RT , et al. Animal models of ' 'mechanisms of SARS-CoV-2 infection and COVID-19 pathology. Br J ' 'Pharmacol 2020;: bph.15143.', 'DOI': '10.22541/au.158861365.54417186'}, { 'key': '2020062211353215000_2020.06.19.159053v1.37', 'doi-asserted-by': 'crossref', 'unstructured': 'Wrapp D , De Vlieger D , Corbett KS , et al. Structural Basis for Potent ' 'Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. ' 'Cell 2020; 181.', 'DOI': '10.1101/2020.03.26.010165'}, { 'key': '2020062211353215000_2020.06.19.159053v1.38', 'unstructured': 'Boulware DR , Pullen MF , Bangdiwala AS , et al. A Randomized Trial of ' 'Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J ' 'Med 2020; NEJMoa2016638.'}, { 'key': '2020062211353215000_2020.06.19.159053v1.39', 'unstructured': 'Horby PW , Landray M. Press release: No clinical benefit from use of ' 'hydroxychloroquine in hospitalised patients with COVID-19. 2020 ' 'https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf ' '(accessed June 16, 2020).'}, { 'key': '2020062211353215000_2020.06.19.159053v1.40', 'doi-asserted-by': 'crossref', 'unstructured': 'Wang Y , Chen L. Lung tissue distribution of drugs as a key factor for ' 'COVID-19 treatment. Br J Pharmacol 2020; bph.15102.', 'DOI': '10.1111/bph.15102'}, { 'key': '2020062211353215000_2020.06.19.159053v1.41', 'doi-asserted-by': 'crossref', 'unstructured': 'Du Y , Chen X. Favipiravir: Pharmacokinetics and Concerns About Clinical ' 'Trials for 2019-nCoV Infection. Clin Pharmacol Ther 2020; cpt.1844.', 'DOI': '10.1002/cpt.1844'}, { 'key': '2020062211353215000_2020.06.19.159053v1.42', 'doi-asserted-by': 'crossref', 'unstructured': 'Chen C , Huang J , Cheng Z , et al. Favipiravir versus Arbidol for ' 'COVID-19: A Randomized Clinical Trial. medRxiv 2020; ' '2020.03.17.20037432.', 'DOI': '10.1101/2020.03.17.20037432'}, { 'key': '2020062211353215000_2020.06.19.159053v1.43', 'doi-asserted-by': 'crossref', 'unstructured': 'Irie K , Nakagawa A , Fujita H , et al. Pharmacokinetics of Favipiravir ' 'in Critically Ill Patients with COVID-19. Clin Transl Sci 2020; cts. ' '12827.', 'DOI': '10.1111/cts.12827'}, { 'key': '2020062211353215000_2020.06.19.159053v1.44', 'doi-asserted-by': 'crossref', 'unstructured': 'Eloy P , Solas C , Touret F , et al. Dose rationale for favipiravir use ' 'in patients infected with SARS-CoV-2. Clin Pharmacol Ther 2020; ' 'cpt.1877.', 'DOI': '10.1002/cpt.1877'}, { 'key': '2020062211353215000_2020.06.19.159053v1.45', 'doi-asserted-by': 'publisher', 'DOI': '10.1371/journal.pntd.0005389'}, { 'key': '2020062211353215000_2020.06.19.159053v1.46', 'doi-asserted-by': 'crossref', 'first-page': '45', 'DOI': '10.1016/S2055-6640(20)30016-9', 'article-title': 'A review of the safety of favipiravir - a potential treatment in the ' 'COVID-19 pandemic?', 'volume': '6', 'year': '2020', 'journal-title': 'J virus Erad'}], 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2020.06.19.159053', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 3, 21]], 'date-time': '2021-03-21T04:25:42Z', 'timestamp': 1616300742000}, 'score': 1, 'resource': {'primary': {'URL': 'http://biorxiv.org/lookup/doi/10.1101/2020.06.19.159053'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 6, 19]]}, 'references-count': 46, 'URL': 'http://dx.doi.org/10.1101/2020.06.19.159053', 'relation': {}, 'subject': [], 'published': {'date-parts': [[2020, 6, 19]]}, 'subtype': 'preprint'}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0